Aysegul A Sahin

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  2. ncbi Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression
    Martin C Abba
    Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, Texas, USA
    Breast Cancer Res 6:R499-513. 2004
  3. ncbi Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer
    Nancy J Poindexter
    Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 6:R408-15. 2004
  4. ncbi Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer
    Mustafa Akkiprik
    Department of Medical Biology, Marmara University, School of Medicine, 34668 Istanbul, Turkey
    Breast Cancer Res 10:212. 2008
  5. ncbi Gene expression signature of estrogen receptor alpha status in breast cancer
    Martin C Abba
    Department of Carcinogenesis, The University of Texas M, d, Anderson Cancer Center, Science Park Research Division, Smithville, Texas, USA
    BMC Genomics 6:37. 2005
  6. ncbi The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer
    Mustafa Akkiprik
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 9:103. 2009
  7. ncbi The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis
    Aijin Wang
    Department of Carcinogenesis, The University of Texas M D Anderson Cancer Center, Smithville, TX, USA
    BMC Cancer 8:268. 2008
  8. ncbi Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer
    Aysegul A Sahin
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Arch Pathol Lab Med 133:869-78. 2009
  9. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
  10. ncbi Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:4691-9. 2004

Detail Information

Publications86

  1. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  2. ncbi Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression
    Martin C Abba
    Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, Texas, USA
    Breast Cancer Res 6:R499-513. 2004
    ..Serial analysis of gene expression (SAGE) was employed to generate a comprehensive global gene expression profile of the major changes occurring during breast cancer malignant evolution...
  3. ncbi Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer
    Nancy J Poindexter
    Department of Bioimmunotherapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Breast Cancer Res 6:R408-15. 2004
    ....
  4. ncbi Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer
    Mustafa Akkiprik
    Department of Medical Biology, Marmara University, School of Medicine, 34668 Istanbul, Turkey
    Breast Cancer Res 10:212. 2008
    ..An in-depth understanding of IGFBP-5 would shed light on its potential role as a target for breast cancer therapeutics...
  5. ncbi Gene expression signature of estrogen receptor alpha status in breast cancer
    Martin C Abba
    Department of Carcinogenesis, The University of Texas M, d, Anderson Cancer Center, Science Park Research Division, Smithville, Texas, USA
    BMC Genomics 6:37. 2005
    ..Thus, producing a breast cancer SAGE database of almost 2.5 million tags, representing over 50,000 transcripts...
  6. ncbi The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer
    Mustafa Akkiprik
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 9:103. 2009
    ..In cancer tissues, IGFBP5 resides mainly in the cytoplasm; however, in transfected cells, IGFBP5 is mainly located in the nucleus. We hypothesized that subcellular localization of IGFBP5 affects its functions in host cells...
  7. ncbi The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis
    Aijin Wang
    Department of Carcinogenesis, The University of Texas M D Anderson Cancer Center, Smithville, TX, USA
    BMC Cancer 8:268. 2008
    ..CK5 is known to be expressed in myoepithelial cells of the mammary gland, suggesting the possibility that transgenic BK5.ATF3 mice may exhibit mammary gland phenotypes...
  8. ncbi Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer
    Aysegul A Sahin
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Arch Pathol Lab Med 133:869-78. 2009
    ..During the past decade sentinel lymph node (SLN) biopsy has been increasingly adopted as a minimally invasive staging alternative to complete axillary node dissection...
  9. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  10. ncbi Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:4691-9. 2004
    ..Radiation should be considered for these patients regardless of their response to initial chemotherapy...
  11. ncbi Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy
    Anees B Chagpar
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
    Ann Surg 243:257-64. 2006
    ..CONCLUSION: Physical examination, ultrasonography, and mammography were only moderately useful for predicting residual pathologic tumor size after neoadjuvant chemotherapy...
  12. ncbi Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:351-7. 2005
    ..Patients with three or more of these factors may benefit from research protocols investigating alternative treatment strategies...
  13. ncbi Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1337-42. 2004
    ..We retrospectively studied whether Her2/neu-positive disease was associated with locoregional recurrence (LRR) after postmastectomy radiotherapy (RT) for breast cancer...
  14. ncbi Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Cell 5:575-85. 2004
    ..DLC1 protein level is elevated in more than 90% of human breast tumors. The regulation of cell survival functions by Pak1-DLC1 interaction represents a novel mechanism by which a signaling kinase might regulate the cancerous phenotypes...
  15. ncbi Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:499-506. 2004
    ....
  16. ncbi Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  17. ncbi Improving local control with breast-conserving therapy: a 27-year single-institution experience
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:20-9. 2005
    ..The current low incidence of IBTR with multidisciplinary management of breast carcinoma may result in more patients choosing BCT over mastectomy...
  18. ncbi Functional implications of altered subcellular localization of PELP1 in breast cancer cells
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:7724-32. 2005
    ....
  19. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  20. ncbi Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry
    Anees Chagpar
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1581-6. 2005
    ..543 and P = 0.540, respectively). CONCLUSIONS: Although the finding of SLN micrometastases by IHC may change management in > 12% of patients, preliminary results suggested that such micrometastases do not affect outcomes significantly...
  21. ncbi Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg Oncol 15:3369-77. 2008
    ..Our goal was to identify clinicopathologic features associated with ITC in patients undergoing sentinel lymph node dissection (SLND)...
  22. ncbi Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
    Ricardo H Alvarez
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:1210-7. 2010
    ....
  23. ncbi Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
    Soley Bayraktar
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2385-93. 2012
    ....
  24. ncbi Role for intraoperative margin assessment in patients undergoing breast-conserving surgery
    Neslihan Cabioglu
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
    Ann Surg Oncol 14:1458-71. 2007
    ..We investigated whether intraoperative margin assessment aids in obtaining negative margins, and to evaluate the local control thus achieved...
  25. ncbi ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
    Jer Yen Yang
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Nat Cell Biol 10:138-48. 2008
    ..Taken together, our study elucidates a novel pathway in cell growth and tumorigenesis through negative regulation of FOXO3a by RAS-ERK and MDM2...
  26. ncbi Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:352-7. 2006
    ..If these findings are confirmed in larger randomized studies, the prognostic index may be useful in helping to select the type of surgical treatment for patients treated with neoadjuvant chemotherapy, surgery, and radiation...
  27. ncbi Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Ian J Bristol
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:474-84. 2008
    ....
  28. ncbi Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience
    Allen M Chen
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2303-12. 2004
    ..Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual disease, and lymphovascular space invasion predict higher rates of LRR and IBTR...
  29. ncbi The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study
    Alberto J Montero
    Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:229-35. 2005
    ..However, despite such improvements, survival rates remained low, and innovative therapeutic approaches are, therefore, needed to improve clinical outcomes...
  30. ncbi Breast conservation after neoadjuvant chemotherapy
    Allen M Chen
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:689-95. 2005
    ..The MDAPI enabled the identification of a small group (4%) of patients who are at high risk for IBTR and LRR and who may benefit from alternative locoregional treatment strategies...
  31. ncbi Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  32. ncbi Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields
    Karen H Shahar
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 59:1074-9. 2004
    ..The remaining patients have a greater risk of having four or more positive lymph nodes, and, therefore, the high axilla/supraclavicular fossa should also be included in the radiation fields...
  33. ncbi Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3315-9. 2005
    ..A secondary objective was to determine whether the quantitative RT-PCR data correlated with immunohistochemistry assay data regarding estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status...
  34. ncbi Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer
    Kapil Mehta
    Department of Experimental Therapeutics Unit 422, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 10:8068-76. 2004
    ..3.2.13). Because the drug-resistant and metastatic phenotypes are thought to share some common pathways, we sought to determine whether metastatic breast cancer cells express high levels of TG2...
  35. ncbi Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer
    Merih Guray Durak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Breast J 17:462-9. 2011
    ..Age at diagnosis and associated FCC are significant factors in predicting recurrence in patients with T1a,bN0 IBC. Adjuvant systemic therapy should be discussed with and considered for young patients with T1a,bN0 IBC...
  36. ncbi PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  37. ncbi Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast
    Ashraful Hoque
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 12:1518-22. 2003
    ..Our data demonstrate that STK15 overexpression correlates with centrosome anomaly and aneuploidy in DCIS, and loss of STK15 overexpression is associated with progression of in situ to ductal invasive breast carcinoma...
  38. ncbi Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy
    Banu K Arun
    Departments of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, USA
    Cancer Invest 28:554-9. 2010
    ..055). Further studies should evaluate the role of GST-pi expression in relation to response to different chemotherapies...
  39. ncbi Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma
    Karen H Shahar
    Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1323-9. 2005
    ..Preoperative lymphoscintigraphy can help to define the nodal basins at risk for harboring disease...
  40. ncbi Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
    Jacqueline S Jeruss
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 26:246-52. 2008
    ..We hypothesized that by using clinical and pathologic staging parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated...
  41. ncbi LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system
    Rozita Bagheri-Yarmand
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Int J Cancer 118:2703-10. 2006
    ..These results suggested an important role for LIMK1 signaling in breast cancer tumor growth, angiogenesis and invasion and a regulatory connection between LIMK1 and the uPA system...
  42. ncbi Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer
    Lin Wang
    Departments of Experimental Therapeutics L W, R Z L, J Y, Z L, A N, R C B, Y Y, Clinical Cancer Prevention A H, S M L, and Pathology J L, A A S, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030
    Clin Cancer Res 9:3660-6. 2003
    ..This study investigated the relationship of ARHI expression to the progression of breast cancer...
  43. ncbi Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy
    Sean E McGuire
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1004-9. 2007
    ..The aim of this study was to investigate the role of postmastectomy radiation therapy in women with breast cancer who achieved a pathologic complete response (pCR) to neoadjuvant chemotherapy...
  44. ncbi Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer
    Yun Wu
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:1507-14. 2012
    ..The clinical significance of occult lymph node metastases has been the subject of debate...
  45. ncbi p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells
    Seetharaman Balasenthil
    Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:1422-8. 2004
    ....
  46. ncbi p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B
    Ratna K Vadlamudi
    Box 108, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Mol Cell Biol 25:3726-36. 2005
    ..TCoB was overexpressed and phosphorylated in breast tumors. These findings reveal a novel role for TCoB and Pak1 in regulating microtubule dynamics...
  47. ncbi Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response
    Darren W Davis
    Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:955-60. 2003
    ..CONCLUSIONS: If the results can be validated in a larger patient cohort, the method could be used to "tailor" therapy to optimize benefit in a patient-specific fashion...
  48. ncbi Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis
    Eugene H Huang
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:490-6. 2007
    ..To evaluate the locoregional efficacy of multimodality treatment for breast cancer patients who present with ipsilateral supraclavicular (SCV) disease without systemic metastases...
  49. ncbi Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy
    Elizabeth A Mittendorf
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:1956-62. 2011
    ..The current study was undertaken to validate this staging system using internal and external cohorts...
  50. ncbi Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system
    Min Yi
    The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 29:4654-61. 2011
    ..We hypothesized that differences in biology influence this variation and that addition of biologic markers to AJCC staging improves determination of prognosis...
  51. ncbi Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer
    Leslie K Diaz
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 18:1165-75. 2005
    ....
  52. ncbi Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer
    Leonel F Hernandez-Aya
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 29:2628-34. 2011
    ..To evaluate the clinical outcomes and relationship between tumor size, lymph node status, and prognosis in a large cohort of patients with confirmed triple receptor-negative breast cancer (TNBC)...
  53. ncbi PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer
    Francisco J Esteva
    Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Pathol 177:1647-56. 2010
    ..In conclusion, PI3K pathway activation plays a pivotal role in trastuzumab resistance. Our findings may facilitate the evaluation of tumor response to trastuzumab-based and targeted therapies...
  54. ncbi Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?
    Lavinia P Middleton
    Department of Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mod Pathol 16:120-9. 2003
    ..Based on these findings, we recommend excisional biopsy of lobular carcinoma in situ, atypical lobular hyperplasia or lobular neoplasia only when it is associated with a synchronous mass lesion...
  55. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  56. ncbi HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy
    Zhibo Yang
    Department of Molecular, Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3198-203. 2003
    ..In summary, these findings show for the first time that HER2 up-regulates PPARgamma expression and modulates the sensitivity of breast cancer cells to PPARgamma ligand therapy...
  57. ncbi Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5652-9. 2003
    ....
  58. ncbi Correlation between CpG methylation profiles and hormone receptor status in breast cancers
    Weiwei Feng
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res 9:R57. 2007
    ..The present study was undertaken to determine whether methylation of a set of growth-suppressor genes would correlate to the expression of estrogen receptors (ERs) and progesterone receptors (PRs)...
  59. ncbi Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion
    Lingegowda S Mangala
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer 4:33. 2005
    ..Two hundred archived samples from patients with breast cancer were studied for the TG2 expression. Also, in an in vitro model the invasive behavior of MDA-MB-231 cells in the presence or absence of exogenous TG2 was determined...
  60. ncbi STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis
    Melanie E Royce
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:12-9. 2004
    ..The authors also explored whether STK15 was a prognostic factor for breast carcinoma by comparing the level of STK15 gene expression with clinical parameters that are known prognostic factors for the disease...
  61. ncbi Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  62. ncbi Detection of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer
    Jijiang Zhu
    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 12:830-7. 2003
    ..These data strongly support the hypothesis that HCA exposure contributes to human breast cancer among genetically susceptible individuals...
  63. ncbi Relationship between epidemiologic risk factors and breast cancer recurrence
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 25:4438-44. 2007
    ..We evaluated the effect of epidemiologic breast cancer risk factors on recurrence in women with early-stage disease...
  64. ncbi Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 36:670-5. 2005
    ..Our results indicate that PELP1 / MNAR and ER beta are coexpressed in most SDCs and may play a role in the pathobiology of these tumors...
  65. ncbi Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma
    Jianzhou Wang
    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:3107-14. 2002
    ....
  66. ncbi NHERF (Na+/H+ exchanger regulatory factor) gene mutations in human breast cancer
    Jia Le Dai
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 23:8681-7. 2004
    ..Taken together, the results indicated NHERF to be a candidate tumor suppressor gene in human breast carcinoma that may be interconnected to the SYK and MERLIN suppressors...
  67. ncbi Contralateral prophylactic mastectomy. Predictors of significant histologic findings
    Katja Goldflam
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA
    Cancer 101:1977-86. 2004
    ..Evaluation of histologic findings in the ipsilateral breast may help to predict the likelihood of significant disease in the contralateral breast and assist in risk stratification...
  68. ncbi Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1150-60. 2003
    ..Over the past decade, it has become increasingly more common to deliver chemotherapy first, but this has raised new questions within all disciplines of cancer management...
  69. ncbi Expression of c-kit proto-oncogene product in breast tissue
    Marwan A Yared
    Department of Pathology, University of Texas-M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Breast J 10:323-7. 2004
    ..These data suggest that c-kit may play a role in breast tumor progression and may therefore have diagnostic, prognostic, and therapeutic implications...
  70. ncbi Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients
    Jamie L Wagner
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 254:119-24. 2011
    ..We evaluated the effect of time to surgery on tumor growth by comparing initial imaging and pathologic tumor size estimates. We also determined predictors of delay to surgery...
  71. ncbi CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation
    Neslihan Cabioglu
    Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6493-7. 2005
    ..We report a novel mechanism of HER2-neu transactivation through SDF-1alpha stimulation of CXCR4 that involves Src kinase activation...
  72. ncbi Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy
    Doina Ivan
    Department of Pathology, The University of Texas-Houston, Houston, TX, USA
    Mod Pathol 17:165-71. 2004
    ..0001) than is the presence of mitoses (P<0.053). A diagnosis of carcinoma or atypical papilloma by CNB should warrant an EB, whereas benign papillomas may be followed if imaging findings are concordant...
  73. ncbi Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Considerations for surgical excision
    Nour Sneige
    Department of Pathology, University of Texas M.D. Anderson Cancer Center, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 119:248-53. 2003
    ..When assessing microcalcifications with ADH, clinicians should consider the percentage of microcalcifications removed by DVAB and the extent of lobular involvement to better assess the need for excision...
  74. ncbi Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..A remarkable diversity in transcriptional response was observed for individual cases. Further data are needed to determine whether gene profiling can predict response to chemotherapy...
  75. ncbi Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer
    Pervez F Firozi
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 23:301-6. 2002
    ..Further large-scale studies are required to determine the exact role of these polymorphisms and types of DNA damage in breast cancer susceptibility...
  76. ncbi Pseudoangiomatous stromal hyperplasia of the breast
    Claudia Y Castro
    Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
    Am J Clin Oncol 25:213-6. 2002
    ..We describe the clinical, radiologic, cytologic, and histologic features of a case of pseudoangiomatous stromal hyperplasia that presented as a rapidly growing breast lesion in a 36-year-old woman...
  77. ncbi Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a Ras signaling component, in human breast tumors
    Christopher J Barnes
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:1251-5. 2002
    ..These findings demonstrate for the first time the receptor-dependent regulation of G3BP, a downstream effector of Ras signaling, by HRG, a growth factor with diverse functions in breast cancer cells...
  78. ncbi Multicentric mammary carcinoma: evidence of monoclonal proliferation
    Lavinia P Middleton
    Department of Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:1910-6. 2002
    ..We also compared the clinical outcomes of the patients in the current study with stage-matched and treatment-matched groups of patients with unicentric mammary carcinoma...
  79. ncbi Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Interferon Cytokine Res 22:583-92. 2002
    ..This activation is associated with a predominantly Th1 cytokine response, which suggests that conditioning with HER-2/neu peptides may be of value in the development of breast cancer vaccines...
  80. ncbi E-cadherin immunohistochemical analysis of histiocytoid carcinoma of the breast
    Deepali Gupta
    Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center, Houston, TX, USA
    Ann Diagn Pathol 6:141-7. 2002
    ..Moreover, the lack of consistent morphologic features, a specific clinical profile, and a distinct immunohistochemical pattern lead us to hypothesize that histiocytoid carcinoma is not a special type of breast cancer...
  81. ncbi Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:880-8. 2002
    ..To compare the pathologic factors associated with postmastectomy locoregional recurrence (LRR) in breast cancer patients not receiving radiation who were treated with neoadjuvant chemotherapy (NEO) vs. adjuvant chemotherapy (ADJ)...
  82. ncbi Genetic and environmental determinants on tissue response to in vitro carcinogen exposure and risk of breast cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:4566-70. 2002
    ..These observations suggest that genetic susceptibility to carcinogen exposure may play an important role in breast carcinogenesis...
  83. ncbi Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts
    Felipe Samaniego
    Department of Lymphoma Myeloma, Clinical Cancer Prevention, Departments of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cell Growth Differ 13:387-95. 2002
    ..KS cells inoculated with neutralizing anti-VEGF antibody did not form tumors. This study supports an important role for VEGF in tumor development and shows how a human tissue can preferentially promote tumor growth...
  84. ncbi Molecular prognostic factors for breast cancer metastasis and survival
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:319-28. 2002
    ..We review the available data supporting the utility of established prognostic and predictive molecular factors, and discuss challenges for integrating novel molecular markers into clinical practice...
  85. ncbi Nuclear factor-kappa B as a predictor of treatment response in breast cancer
    Amit K Garg
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA
    Curr Opin Oncol 15:405-11. 2003
    ..Gaining further insights into molecular factors such as NF-kappa B as biomarkers for treatment response may help clinicians predict treatment outcome and lead to the development of targeted therapeutics...
  86. ncbi Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215
    Ratna K Vadlamudi
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    FEBS Lett 543:76-80. 2003
    ..These findings suggest that HER2/HRG influence metastasis of breast cancer cells through a novel signaling pathway involving phosphorylation of FAK tyrosine 861 via activation of c-Src tyrosine 215...